Oslo, Norway, 19 May 2021: Reference is made to the stock exchange release by
Photocure ASA ("Photocure" or the "Company") (OSE: PHO) published on 15
September 2021 regarding 370,000 share options granted conditionally.

The board of directors in Photocure ASA has today decided to convert a total of
370,000 conditional share options to unconditional share options.

Of the total share option conversion, the following unconditional share options
were converted for primary insiders:

  · Dan Schneider, CEO, has received 60,000 share option, new total holding of
share options 210,000
  · Erik Dahl, CFO, has received 35,000 share option, new total holding of share
options 65,000
  · Geoffrey Coy, VP and General Manager of U.S. Operations, has received 35,000
share option, new total holding of share options 102,500
  · Grete Hogstad, VP Global Strategic Marketing & Business Development, has
received 25,000 share option, new total holding of share options 43,750
  · Kari Myren, VP Global Medical Affairs and Clinical Development, has received
25,000 share option, new total holding of share options 43,750

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.